The global Analytical Standards Market, valued at US$1.44 billion in 2022, is forecasted to grow at a robust CAGR of 5.9%, ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

"If you want to be an effective leader, it starts with self-awareness," former PepsiCo General Counsel David Yawman said. "Do I understand what I stand for? What I’m great at? What triggers me into ...

Sun Pharmaceutical Industries Ltd. closed 11.47% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19. Does this ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely comprehensive and reliable manner.

Graphic: Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies for the Seventh Consecutive Year. Used with ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Efforts to reduce the size of government agencies and the expansion of tariffs are “neutral to negative for health care ...